Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice

Epilepsia

Volumn 40, Issue SUPPL. 10, 1999, Pages s48-s56

  Pisani, Francesco ^a,c   Spina, Edoardo ^b   Oteri, Giancarla ^a  

^a Inst Neurol and Neurosurgical Sci   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Policlinico   (Italy)

Author keywords

Antidepressant drugs; Depression; Epilepsy; Seizure risk

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUTRIPTYLINE; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TOLOXATONE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE; ZIMELDINE;

ANTICONVULSANT ACTIVITY; CONFERENCE PAPER; DEPRESSION; DOSE RESPONSE; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG STRUCTURE; EPILEPTOGENESIS; HUMAN; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEIZURE; SEIZURE SUSCEPTIBILITY; SEROTONINERGIC TRANSMISSION;

EID: 0032804621     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00885.x     Document Type: Conference Paper

References (122)

1. Edwards JG, Long KS, Sedgwick EM, Wheal HV. Antidepressants and convulsive seizures: clinical, electroencephalographic and pharmacological aspects. Clin Neuropharmacol 1986;9:329-60.
2. Robertson MM. Depression in patients with epilepsy reconsidered. In: Pedley TA, Meldrum BS, eds. Recent advances in epilepsy. Vol. 4. Edinburgh, London, Melbourne, New York, Tokyo: Churchill-Livingstone. 1989:205-40.
3. Matthews WS, Barabas G. Suicide and epilepsy: a review of the literature. Psychosomatics 1981;22:515-24.
4. Robertson MM. The organic contribution to depressive illness in patients with epilepsy. J Epilepsy 1989;2:189-223.
5. Leyberg JT, Denmark JC. The treatment of depressive states with imipramine hydrochloride (Tofranil). J Ment Sci 1959;105: 1123-6.
6. Blair D. Treatment of severe depression by imipramine. An investigation of 100 cases. J Ment Sci 1960;106:891-905.
7. Sharp WL. Convulsions associated with anti-depressant drugs. Am J Psychiatry 1960;117:458-9.
8. Betts TA, Kalra PL, Cooper R, Jeavons PM. Epileptic fits as a probable side-effect of amitriptyline. Report of seven cases. Lancet 1968;1:390-2.
9. Dallos V, Heathfield K. Iatrogenic epilepsy due to antidepressant drugs. BMJ 1969;4:80-2.
10. Kiloh LG, Davison K, Ossleton JW. An electroencephalographic study on the analeptic effects of imipramine. Electroencephalogr Clin Neurophysiol 1961;12:165-72.
11. Davison K. EEG activation after intravenous amitriptyline. Electroencephalogr Clin Neurophysiol 1965;19:298-300.
12. Redding FK. EEG activation with amitriptyline. Electroencephalogr Clin Neurophysiol 1969;26:630-6.
13. Legg NJ, Swash M. Clinical note: seizures and EEG activation after trimipramine. Epilepsia 1974;15:131-5.
14. Rumpl E, Hinterhuber H. Unusual spike-wave stupor in a patient with manic-depressive psychosis treated with amitriptyline. J Neurol 1981;226:131-5.
15. Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989;8:296-329.
16. Braitberg G, Curry SC. Seizure after isolated fluoxetine overdose. Ann Emerg Med 1995;26:234-7.
17. Trabert W, Hohagen F, Winkelmann G, Berger M. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Pharmacopsychiatry 1995;28:95-7.
18. Personne M, Sjoberg G, Persson H. Citalopram overdose. Review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997;35:237-40.
19. Fromm GH, Amores CY, Thies W. Imipramine in epilepsy. Arch Neurol 1972;27:198-204.
20. Fromm GH, Rosen JA, Amores CY. A clinical and experimental investigation of the effect of imipramine on epilepsy. Epilepsia 1971;12:282-3.
21. Fromm GH, Wessel HB, Glass JD, Alvin JD, Van Horn G. Imipramine in absence and myoclonic-astatic seizures. Neurology 1978;28:953-7.
22. Ojemann LM, Friel PN, Trejo WJ, Dudley DL. Effect of doxepine on seizure frequency in depressed epileptic patients. Neurology 1983;33:646-8.
23. Leander JD. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide (LY201116). Epilepsia 1992;33:573-6.
24. Prendville S, Gale K. Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 1993;34: 381-4.
25. Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. Anticonvulsant effect of fluoxetine in humans. Neurology 1995;45: 1926-7.
26. Sakakihara Y, Oka A, Kubota M, Ohashi Y. Reduction of seizure frequency with clomipramine in patients with complex partial seizures. Brain Dev 1995;17:291-3.
27. Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996; 52:1323-9.
28. Chadwick D. Drug-induced convulsions. In: Rose FE, ed. Research progress in epilepsy. London: Pittman Press, 1983:151-60.
29. Zaccara G, Muscas GC, Messori A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Safety 1990;5:2-43.
30. Showron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992;12:18-22.
31. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289-99.
32. Duncan D, Taylor D. Which is the safest antidepressant to use in epilepsy? Psychiatr Bull 1995;19:355-7.
33. Torta R, Keller R, Monaco F. Seizures, epilepsy and pharmacotherapy of depression: a comparison among tricyclic antidepressants, atypical and SSRI. Boll Lega It Epilessia 1996;94:17-28.
34. Alldredge BK. Drug induced seizures: controversies in their identification and management. Pharmacotherapy 1997;17:857-60.
35. Leber P. "Time-less" risks (a hazard of risk assessment: the example of seizure and antidepressants). Psychopharmacol Bull 1985;21:334-8.
36. Trimble MR. Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review. Epilepsia 1978;19:241-50.
37. Jick H, Dinan BJ, Hunter JR, et al. Tricyclic antidepressant and convulsions. J Clin Pharmacol 1983;3:182-5.
38. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983;44:197-201.
39. Jabbari B, Bryan G, Mars LE, Gunderson CH. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985;42:480-1.
40. Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981;2:93-4.
41. Edwards JG, Glen-Bott M. Does viloxazine have epileptogenic properties? J Neurol Neurosurg Psychiatry 1984;47:960-4.
42. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression: a perspective on seizures. Arch Gen Psychiatry 1986;43:86-90.
43. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989;50:256-61.
44. Physician's Desk Reference, Prozac. Montvale, NJ: Medical Economics, 1992:921.
45. Edwards JG, Inman WHW, Wilton L, Pearce GL. Prescription-event monitoring of 10,401 patients treated with fluvoxamine. Br J Psychiatry 1994;164:387-95.
46. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975;16:1-66.
47. Delay J, Deniker P. Efficacy of Tofranil in the treatment of various types of depression: a comparison with other antidepressant drugs. Can Psychiatr Assoc J 1959;4:100-12.
48. Freyhan FA. Clinical effectiveness of Tofranil in the treatment of depressive psychoses. Can Psychiatr Assoc J 1959;4:86-9.
49. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P. Adverse reaction to mono amine oxidase inhibitors, part I: a comparative study. J Clin Psychopharmacol 1984;4:270-8.
50. Burley DM. A brief note on the problem of epilepsy in antidepressant treatment. In: Jukes A, ed. Depression - the biochemical and physiologic role of ludiomil. Horsham, UK: CIBA, 1977:201-3.
51. Horne RL, Ferguson JM, Pope HG, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988;49:262-6.
52. Lowry MR, Dunner FJ. Seizures during tricyclic therapy. Am J Psychiatry 1980;137:1461-2.
53. Edwards JG, Glen-Bott M. Mianserin and convulsive seizures. Br J Clin Pharmacol 1983;15:299-311.
54. Wroblewski BA, McColgan K, Smith K, Whyte J, Singer WD. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990;10:124-8.
55. Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997;96:379-84.
56. Richens A, Nawishy S, Trimble MR. Antidepressant drugs, convulsions, and epilepsy. Br J Clin Pharmacol 1983;15:295-8.
57. Perucca E, Manzo L, Crema A. Pharmacokinetic interaction between antiepileptic and psychotropic drugs. In: Trimble MR, ed. The psychopharmacology of epilepsy. Chichester, UK: John Wiley & Sons, 1985;95-105.
58. Pisani F, Perucca E, Di Perri R. Clinically relevant antiepileptic drug interactions. J Int Med Res 1990;18:1-15.
59. Sedgwick EM, Edwards JG. Mianserin, maprotiline and the electroencephalogram. Br J Clin Pharmacol 1983; 15:255-62.
60. Atril PB, Julius DA. Maprotile hydrochloride associated with a clinical state of catatonic stupor and epileptic encephalogram. J Clin Psychopharmacol 1984;4:207-9.
61. Trimble MR. New antidepressant drugs and the seizure threshold. Neuropharmacology 1980;19:1227-8.
62. Lefkowitz D, Kilgo G, Lee S. Seizures and trazodone therapy. Arch Gen Psychiatry 1985;42:523.
63. De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43:40-7.
64. Schindler BA, Ramcandani D. Partial complex status epilepticus in a lithium-toxic patient. Psychosomatics 1993;4:521-4.
65. Krijzer F, Snelder N, Bradford D. Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in the animal model. Neuropsychobiology 1984;12:249-54.
66. Showron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992;12:18-22.
67. Wedin GP, Oderda GM, Klein-Schwartz W, Gorman RL. Relative toxicity of cyclic antidepressants. Ann Emerg Med 1986;57: 797-804.
68. Goel KM, Shanks RM. Amitriptyline and imipramine poisoning in children. BMJ 1974;1:261-3.
69. Biggs JT, Spiker DG, Petit GM, Ziegler VE. Tricyclic antidepressant overdose: incidence of symptoms. JAMA 1977;238: 135-8.
70. Petit JM, Spiker DG, Ruwitch JF, Ziegler VE. Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin Pharmacol Ther 1977;21:47-51.
71. Crome P, Newman B. The problem of tricyclic antidepressant poisoning. Postgrad Med J 1979;55:528-32.
72. Frommer DA, Kulig KW, Marx GA, Rumack B. Tricyclic antidepressant overdose: a review. JAMA 1987;257:521-6.
73. Olson KR, Kearney TE, Dver JE, Benowitz NL, Blanc PD. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994;12:392-5.
74. Preskorn SH, Othmer SC, Lai CW, Othmer E. Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations. J Clin Psychopharmacol 1984;4:262-4.
75. Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985;313:474-9.
76. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992;53:160-2.
77. Pascual J, Combarros O, Berciano J. Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment. Clin Neuropharmacol 1987;10:265-7.
78. Devanand DP, Sackeim HA, Brown RP. Myoclonus during combined tryciclic antidepressant and lithium treatment. J Clin Psychopharmacol 1988;8:446-7.
79. Avoni P, Riva R. Albani F. Recurrence of absence seizures induced by a low dose of amitriptyline: a case report. Eur J Neurol 1996;3:272-4.
80. DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997;19:71-3.
81. Miyata H, Kubota F, Shibata N, Kifune A. Non-convulsive status epilepticus induced by antidepressants. Seizure 1997;6/5:405-7.
82. Yoshino A, Watanabe M, Shimizu K, et al. Nonconvulsive status epilepticus during antidepressant treatment. Neuropsychobiology 1997;35:91-4.
83. Baldessarini RJ, Teicher MH, Cassidy JW. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1988;8:381.
84. Troupin AS, Ojemann LM. Paradoxical intoxication - a complication of anticonvulsant administration. Epilepsia 1975;16: 753-8.
85. Johnsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984;16:392-3.
86. Lerman P. Seizures induced or aggravated by anticonvulsants. Epilepsia 1986;27:706-10.
87. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
88. Dersun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993;342: 442-3.
89. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992;55:412-3.
90. Spina E, Perucca E. Newer and older antidepressants. A comparative review of drug interactions. CNS Drugs 1994;2:479-87.
91. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharm Ther 1990; 46:377-94.
92. Brosen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.
93. Monaco F, Torta R. Interactions between antiepileplic and psychoactive agents: the impact of drug monitoring | Abstract|. In: Luching CH, Feuerstein TJ, eds. Proc 1st Ear Congr Clin Neuropharmacol, 1994;47.
94. Power BM, Hackert LP, Dusci LJ, Ilett KF. Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Clin Pharmacokinet 1995;29:154-71.
95. Luchins DJ, Oliver AP, Wyatt RJ. Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 1984;25: 25-32.
96. Lange SC, Julien RM, Fowler GW. Biphasic effects of imipramine in experimental models of epilepsy. Epilepsia 1976;17:183-96.
97. Vernier VG. The pharmacology of antidepressant agents. Dis Nerv Syst 1961;22:7-13.
98. Chen G, Ensor CR, Bohner B. Studies of drug effects on electrically induced extensor seizures and clinical implications. Arch Int Pharmacodyn Ther 1968;172:183-218.
99. Stille G, Sayers A. The effect of antidepressant drugs on the convulsive excitability of brain structures, Int J Neuropharmacol 1964;3:605-9.
100. Woods TW, Jobe PC, Laird HE, Dailey JW. Anticonvulsant and proconvulsant doses of desipramine in the genetically epilepsy-prone rat. Fed Proc 1983;42:363.
101. Meldrum BS, Anlezark GM, Adam HK, Greenwood DT. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology 1982;76:212-7.
102. Woods TW, Dailey JW, Reigel CE, Jobe PC. Anticonvulsant and proconvulsant effects of doxepin in genetically epilepsy prone rat (GEPR). Fed Proc 1985;44:1107.
103. Trimble MR, Anlezark G, Meldrum BS. Seizure activity in photosensitive baboons following antidepressant drugs and the role of scrotonergic mechanisms. Psychopharmacology 1977;51:159-64.
104. Koella WP, Glatt A, Klebs K, Durst T. Epileptic phenomena induced in the cut by the antidepressants maprotiline, imipramine, clomipramine and amitriptyline. Biol Psychiatry 1979;14:485-97.
105. Jobe PC, Woods TW, Dailey JW. Pro-convulsant and anticonvulsant effects of tricyclic antidepressants in genetically epilepsy-prone rats. In: Porter RJ, Mattson J, Richard H, Ward AA Jr, Dam M, eds. Advances in epileptology: 15th Epilepsy International Symposium. New York: Raven Press, 1984:187-91.
106. Meldrum BS. The effect of psychotropic drugs on the seizure threshold: animal studies. In: Trimble RM, ed. The psychopharmacology of epilepsy. Chichester, New York, Brisbane, Toronto, Singapore: John Wiley & Sons, 1985:107-17.
107. Millichap JG. Anticonvulsant drugs. In: Root WS, Hofmann FG, eds. Physiological pharmacology: a comprehensive treatise. New York: Academic Press, 1965:97-173.
108. Setiey A, Courjon J. Clomipramine et petit mal. Lyon Med 1978; 239:751-4.
109. Tassinari CA, Dravet G, Roger J, Cano JP, Gastaut H. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972;13: 421-35.
110. Bittencourt PR, Richens A. Anticonvulsant induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1981;22:129-34.
111. Willner P. Antidepressants and serotonergic neurotransmission: an integrative review. Psychopharmacology 1985;85:387-404.
112. Altshuler HL, Killam EK, Killam KF. Biogenic amines and the photo-myoclonic syndrome in the baboon, Papio papio. J Pharmacol Exp Ther 1976;196:156-66.
113. Chadwick D, Jenner P, Reynolds EH. Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs. Ann Neurol 1977;1:218-24.
114. Snead OC. On the sacred disease: the neurochemistry of epilepsy. Int Rev Neurobiol 1983;24:93-180.
115. Deahl M, Trimble MR. Serotonin reuptake inhibitors, epilepsy and myoclonus. Br J Psychiatry 1991;159:433-5.
116. Wada Y, Nakamura M, Hasegowa H, Yamaguchi N. Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett 1992;141:21-4.
117. Sackeim HA, Decina P, Prohovnik I, Malitz, S, Resor SR. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biol Psychiatry 1983; 18:1301-10.
118. Post RM, Putnam F, Uhde TW, Weiss SRB. Electroconvulsive therapy as an anticonvulsant: implications for its mechanism of action in affective illness. In: Malitz S, Sackeim HA, eds. Electroconvulsive therapy: clinical and basic research issues. Ann NY Acad Sci 1986;462:376-88.
119. Coffey CE, Lucke J, Weiner RD, Kristal AD, Aque M. Seizure threshold in electroconvulsive therapy (ECT) II: the anticonvulsant effect of ECT. Biol Psychiatry 1995;37:777-88.
120. Griesemer DA, Kellner CH, Beale MD, Smith GM. Electroconvulsive therapy for treatment of intractable seizures. Initial findings in two children. Neurology 1997;49:1389-92.
121. Reynolds EH, Travers RD. Serum anticonvulsant concentrations in epileptic patients with mental symptoms. Br J Psychiatry 1974; 124:440-5.
122. Fischbacher E. Effect of reduction of anticonvulsants on wellbeing. BMJ 1982;285:425-7.